Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOPANC-6: MesoPher in ABC Borderline Resectable Pancreatic Cancer
2025-523134-28-00Phase 3Authorised
- Sponsor
- Erasmus MC
- Start
- May 2026
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of MesoPher in pancreatic cancer (PC) (2 arms), sponsored by Erasmus MC. Primary endpoints: Phase II progression-free survival and Phase III overall survival. Planned start May 2026; status: authorised.
02
Drugs
MesoPher
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2025-523134-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523134-28-00.